Achieve Life Sciences Inc (SP4P) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Achieve Life Sciences Inc (SP4P) has a cash flow conversion efficiency ratio of -0.835x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-17.98 Million ≈ $-21.02 Million USD) by net assets (€21.52 Million ≈ $25.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Achieve Life Sciences Inc fund operations to measure how many days the company can operate on defensive assets alone.
Achieve Life Sciences Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Achieve Life Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Achieve Life Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Achieve Life Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tianjin Binhai Energy & Development Co Ltd
SHE:000695
|
-0.102x |
|
The Anup Engineering Limited
NSE:ANUP
|
-0.098x |
|
Prothena Corporation plc
NASDAQ:PRTA
|
-0.138x |
|
HANGZHOU TIGERMED CO. H 1
F:5HZ1
|
N/A |
|
Fenix Outdoor International AG
ST:FOI-B
|
-0.029x |
|
Bright Oceans Inter Telecom Corp
SHG:600289
|
-0.244x |
|
Carter Bank and Trust
NASDAQ:CARE
|
0.028x |
|
Huatian Hotel Group Co Ltd
SHE:000428
|
0.016x |
Annual Cash Flow Conversion Efficiency for Achieve Life Sciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Achieve Life Sciences Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see SP4P market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €21.52 Million ≈ $25.16 Million |
€-49.47 Million ≈ $-57.83 Million |
-2.299x | -61.38% |
| 2024-12-31 | €20.90 Million ≈ $24.43 Million |
€-29.77 Million ≈ $-34.80 Million |
-1.424x | -108.43% |
| 2023-12-31 | €-1.45 Million ≈ $-1.69 Million |
€-24.48 Million ≈ $-28.62 Million |
16.905x | +473.82% |
| 2022-12-31 | €8.30 Million ≈ $9.71 Million |
€-37.55 Million ≈ $-43.90 Million |
-4.522x | -330.76% |
| 2021-12-31 | €28.04 Million ≈ $32.78 Million |
€-29.44 Million ≈ $-34.42 Million |
-1.050x | -190.52% |
| 2020-12-31 | €37.29 Million ≈ $43.59 Million |
€-13.47 Million ≈ $-15.75 Million |
-0.361x | +57.13% |
| 2019-12-31 | €18.05 Million ≈ $21.10 Million |
€-15.22 Million ≈ $-17.79 Million |
-0.843x | -25.40% |
| 2018-12-31 | €15.80 Million ≈ $18.47 Million |
€-10.62 Million ≈ $-12.42 Million |
-0.672x | +41.84% |
| 2017-12-31 | €7.88 Million ≈ $9.21 Million |
€-9.11 Million ≈ $-10.65 Million |
-1.156x | -10752.47% |
| 2016-12-31 | €18.97 Million ≈ $22.17 Million |
€-202.00K ≈ $-236.16K |
-0.011x | -- |
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreement… Read more